Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

BACKGROUND: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20–30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determina...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Hematol Oncol
Päätekijät: Wang, Shuhang, Su, Xiaomei, Bai, Hua, Zhao, Jun, Duan, Jianchun, An, Tongtong, Zhuo, Minglei, Wang, Zhijie, Wu, Meina, Li, Zhenxiang, Zhu, Jian, Wang, Jie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2015
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643502/
https://ncbi.nlm.nih.gov/pubmed/26563758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0210-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia